Cholesteryl ester transfer protein and its inhibitors
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Most of the cholesterol in plasma is in an esterified form that is generated in potentially cardioprotective HDLs. Cholesteryl ester transfer protein (CETP) mediates bidirectional transfers of cholesteryl esters (CEs) and triglycerides (TGs) between plasma lipoproteins. Because CE originates in HDLs and TG enters the plasma as a component of VLDLs, activity of CETP results in a net mass transfer of CE from HDLs to VLDLs and LDLs, and of TG from VLDLs to LDLs and HDLs. As inhibition of CETP activity increases the concentration of HDL-cholesterol and decreases the concentration of VLDL- and LDL-cholesterol, it has the potential to reduce atherosclerotic CVD. This has led to the development of anti-CETP neutralizing monoclonal antibodies, vaccines, and antisense oligonucleotides. Small molecule inhibitors of CETP have also been developed and four of them have been studied in large scale cardiovascular clinical outcome trials. This review describes the structure of CETP and its mechanism of action. Details of its regulation and nonlipid transporting functions are discussed, and the results of the large scale clinical outcome trials of small molecule CETP inhibitors are summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 2×
“not known with certainty, but it may have been the consequence of serious off-target adverse effects of the drug (70), including increased blood pressure, increased synthesis”
BackgroundSelf-citationEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 3×
“Treatment with dalcetrapib did not reduce ASCVD events (106).”
BackgroundResultInfluentialSelf-citationEffects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801 · cited 1×
“approximately 12,500 high-risk statin-treated patients randomized in a double-blind design to receive evacetrapib or placebo (107).”
BackgroundSelf-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774 · cited 1×
“the lipid profile changes that occur in humans and animals with CETP deficiency (12, 91).”
BackgroundSafety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Self-citationCai, L., Ji, A., de Beer, F. C., Tannock, L. R., & van der Westhuyzen, D. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci31539 · Cited by 167 · cited 1×
“Hepatic uptake of HDL CEs by scavenger receptor B1 has also been implicated in LPS clearance (77).”
BackgroundGenetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Johannsen, T. H., Frikke-Schmidt, R., Schou, J., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.045 · Cited by 156 · cited 4×
“Perhaps the most compelling genetic evidence in favor of CETP activity being pro-atherogenic comes from the Copenhagen City Heart Study (53) and from a study that examined the effect of protein-truncating variants of the CETP gene (54).”
BackgroundInfluentialGotto, A. M., Cannon, C. P., Li, X. S., Vaidya, S., Kher, U., Brinton, E. A., Davidson, M., Moon, J. E., Shah, S., Dansky, H. M., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.041 · Cited by 86 · cited 1×
“In a long-term follow-up of participants in the DEFINE trial, it was found that anacetrapib accumulated in adipose tissue and remained detectable in the body for two or more years after the last dose of the drug (109).”
BackgroundSelf-citationNiu, W., & Qi, Y. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000748 · Cited by 35
Rocco, D. D. F. M., Okuda, L. S., Pinto, R. S., Ferreira, F. D., Kubo, S. K., Nakandakare, E. R., Quintão, E. C. R., Catanozi, S., & Passarelli, M. (2011) · Lipids · doi:10.1007/s11745-011-3555-z · Cited by 33 · cited 1×
“However, aerobic exercise has been reported not to affect CETP activity in mice transgenic for the human CETP gene (38) or plasma CETP levels in humans (39, 40).”
Background6-mo aerobic exercise intervention enhances the lipid peroxide transport function of HDL
Tiainen, S., Luoto, R., Ahotupa, M., Raitanen, J., & Vasankari, T. (2016) · Free Radical Research · doi:10.1080/10715762.2016.1252040 · Cited by 23 · cited 1×
“However, aerobic exercise has been reported not to affect CETP activity in mice transgenic for the human CETP gene (38) or plasma CETP levels in humans (39, 40).”
Background
Cited by
Molecular Pathways Underlying Cholesterol Homeostasis
Afonso, M. S., Machado, R. M., Lavrador, M., Quintao, E. C. R., Moore, K., & Lottenberg, A. (2018) · Nutrients · doi:10.3390/nu10060760 · Cited by 138
Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?
De Marco, D., Pencina, K., Pencina, M., Dufresne, L., Thanassoulis, G., & Sniderman, A. D. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.05.093 · Cited by 15
Hepatic Lipoprotein Metabolism: Current and Future In Vitro Cell-Based Systems
Kiss, I., Neuwert, N., Oberle, R., Hengstschläger, M., Osmanagic-Myers, S., & Stangl, H. (2025) · Biomolecules · doi:10.3390/biom15070956 · Cited by 11
“Within HDL, cholesterol is esterified by lecithin–cholesterol acyltransferase (LCAT) and partially exchanged for triglycerides from LDL or VLDL particles via a CETP-mediated process [18,19].”
Metadata
- Authors
- Shrestha, S., Wu, B. J., Guiney, L., Barter, P. J., & Rye, K.-A.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2018
- Volume
- 59
- Issue
- 5
- Pages
- 772-783
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2788642078
- Cited by
- 104
- References
- 12
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.